Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 September 2021 | Story Nonsindiso Qwabe | Photo Supplied
Dr Samantha Potgieter.

As COVID-19 vaccines continue to be a topical issue in South Africa and indeed in the world itself, the Department of Human Resources held a webinar for the UFS community on 10 September that delved deeper into the questions surrounding the vaccine. 

Dr Samantha Potgieter, infectious disease expert at the Universitas Academic Hospital and affiliated Lecturer in the Department of Internal Medicine at the University of the Free State, addressed some commonly raised concerns about the COVID-19 vaccine and how it affects us.

Dr Potgieter started off by saying that coronaviruses have been causing outbreaks among humans for millennia. While COVID-19 is relatively mild and self-limiting in 80% of patients, 20% of patients are at risk of developing severe disease.
She said before a vaccine could be introduced to a population, it had to go through rigorous testing and clinical trials. Only once safety has been confirmed, it can be released and distributed. 

“This process usually takes about ten years; this is what we are used to. But it has happened much quicker for the COVID-19 vaccine, and I think this is a fact that many people misinterpret – that the evidence might not be that robust, which is certainly not the case. COVID-19 vaccines have gone through all this rigorous testing, thousands of patients had volunteered for trial testing studies. The point is that we already had the technology, vaccination is not something new to humans. So, these preclinical trials were able to happen very quickly, and because of the large number of infections and because the focus of the entire world was on finding a cure, it was a very set process to get these trials through the adequate phases.” 

She said the COVID-19 vaccine was approved by national regulators, manufactured to exacting standards, and only thereafter distributed – as is the case for all drugs released into the market.

How does the vaccine work?

Dr Potgieter said the vaccine works by producing antibodies against the COVID-19 virus. If you are infected with the COVID-19 virus after getting vaccinated, these antibodies bind to the virus and stop it from replicating.

“When you get infected with a disease such as COVID-19, natural antibodies are produced by the immune system to fight the disease. If you get infected again, the immune system will remember how to respond, and quickly destroy the virus. A vaccine can do the same, but without the risk of disease from natural infection. Vaccines work by imitating a bacteria or virus using either mRNA in the case of the COVID-19 vaccine, or a dead or weakened version of the bacteria or virus. The vaccine raises the body’s alarm. It trains the body to recognise and fight the virus. When the body encounters the real-deal virus, it is primed and ready to fight for the body’s health.”

She said South Africa had the mRNA vaccine in the form of the Pfizer vaccine, and the adenoviral vector vaccine in the form of the Johnson & Johnson vaccine.

Why should you get the vaccine?

Dr Potgieter said vaccines are safe and effective, and the most compelling reasons for getting vaccinated are the following:

-To protect yourself from severe disease
-To protect those around you who may be at risk of severe disease
-To restore the social and economic platforms of the country, and the world at large.
She said that while the vaccine does not prevent you from getting COVID-19, it offers better protection against the development of severe disease, and vaccinated people had 50% less chance of spreading the virus.
The most common side effects of the vaccine are the following:
-Pain at the injection site
-Swollen lymph nodes
-Fever
-Fatigue
-Headache
-Myalgia (muscle pain)

“These are indications that the immune system is mounting a response. When it mounts a response, it produces antibodies,” she said.

Answers to commonly asked questions are the following:

1. Can the vaccine alter my DNA?
“No, it goes nowhere near the nucleus of the cell.”

2. What happens when you get COVID in between the first and second doses?
“Some protection is conferred after the first dose, but maximum protection is conferred two weeks after the second dose. Vaccination is still advised.” 

Dr Potgieter said patients who were between vaccinations still show better recovery results than those without.

3. What about natural immunity?
“Natural immunity might confer better protection, but it runs the risk of severe disease. Yes, immunity can be gained through natural immunity, it can be gained through vaccination, and it can certainly be gained by a combination of the two.”

4. What about long-term side effects?
“Serious side effects that cause long-term health problems following any vaccination are very rare, including the COVID-19 vaccination.”

To get the answers to more of your questions, the webinar can be accessed via the following link: https://event.webinarjam.com/go/replay/43/053q6a8vay9a0qa2

News Archive

Out-of-the-box thinking a plus for next generation of agribusiness leaders
2017-07-07

Description: Agribusiness leaders Tags: Agribusiness leaders 

The winners of the 12th IFAMA International Student
Case Competition from Team South Africa are from
the left: JW Swanepoel, University of the Free State,
Melissa van der Merwe, University of Pretoria,
Heinrich Jantjies, Stellenbosch University, and
Johann Boonzaaier, also from Stellenbosch University.
Photo: Supplied



The International Food and Agribusiness Management Association’s International Student Case Competition, in its 12th year, brings together students from around the world to demonstrate their investigative and problem-solving skills to provide innovative solutions to practical problems.

JW Swanepoel, a PhD student at the Centre for Sustainable Agriculture at the University of the Free State (UFS) was part of an advanced case study team, representing South African universities, who won IFAMA’s International Student Case Competition. Swanepoel also presented results from his PhD study at IFAMA’s conference in Miami, Florida, where the winners were announced.

Competition a global stage to showcase solutions

The competition provides a global stage for students and their associated universities to showcase the next generation of agribusiness leaders.

This year the featured agribusiness was Bayer Crop Science. Although this company managed to expand its global footprint through its Food Chain Partnership, it faced some challenges to expand in emerging economies through small-scale farmers. Being from the African continent, Swanepoel and his team not only understood Bayer’s unique challenge but could also pre-empt some of the potential problems faced by agribusinesses that wanted to grow their footprint in emerging economies. This provided them with a competitive advantage in going head-to-head with some of the best universities in the world such as Purdue, Wageningen, Michigan, Texas A & M and Santa Clara to mention just a few.

The South African team’s presentation “Selling Lindiwe’s story” told the story of a small-scale woman cassava farmer in Mozambique who, after the death of her husband, became the main breadwinner. The South African team indicated how Bayer could play a major role in not only selling chemicals to these farmers but even more importantly to change the stories of small-scale farmers like Lindiwe. They recommended a strategic partnership with AB InBev as the main buyer for the cassava produced by these small-scale farmers, as a cheaper beer base substitute. They also recommended a local partner (Value Chain Insights) that understood the political, social and economic environment of these countries to facilitate the relationships between Bayer and its small-scale farmers.

Understanding the challenge a competitive advantage

According to the panel of judges, the innovative approach and motivations for investing in strategic partnerships with AB InBev and Value Chain Insights went beyond financial benefits, to include corporate social responsibility and rural development. Lindiwe’s story was, however, the decisive factor. The South African team was the only team to put a face and a story to the often invisible small-scale farmers.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept